XPH
State Street SPDR S&P Pharmaceuticals ETF
SPDR Pharmaceuticals ETF objective is to replicate as closely as possible the performance of the S&P Pharmaceuticals Select Industry Index, an equal-weighted index.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 507.8 M
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Jun 19, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| CRINETICS PHARMACEUTICALS INC | 3.7 % |
| MBX BIOSCIENCES INC | 3.2 % |
| DEFINIUM THERAPEUTICS INC | 2.8 % |
| ATAIBECKLEY INC | 2.8 % |
| AMYLYX PHARMACEUTICALS, INC. | 2.3 % |
| ENLIVEN THERAPEUTICS, INC. | 2.2 % |
| CORCEPT THERAPEUTICS INC | 2.2 % |
| ALUMIS INC | 2.1 % |
| NUVATION BIO INC CLASS A | 2.1 % |
| TREVI THERAPEUTICS, INC. | 2.1 % |
Constituent Breakdown
| Number of holdings | 60 |
| Herfindahl-Hirschman Index | 176 |
| Wgt avg mkt cap (mns) | $40,923 |
| Large cap (>$10bn) | 17.6% |
| Mid cap ($2-10bn) | 33.7% |
| Small cap (<$2bn) | 39.1% |
| Developed mkts. | 92.1% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 86.7 % |
 |
IRELAND | 3.0 % |
 |
SINGAPORE | 1.5 % |
 |
CAYMAN ISLANDS | 0.9 % |
Historical Performance
Standardized Performance (as of 07/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 21.5% | 65.2% | 25.5% | 15.9% | 6.2% | 4.0% | 7.4% | 7.6% |
| Dividend Yield | 0.3% | 1.1% | 1.3% | 1.4% | 1.4% | 1.0% | 1.8% | 1.8% |
| Total Returns | 21.8% | 66.3% | 26.7% | 17.3% | 7.6% | 5.0% | 9.2% | 9.4% | Ann. Volatility | 24.3% | 22.6% | 22.4% | 20.7% | 21.0% | 22.1% | 22.1% | 22.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.75 | 18% |
| MSCI EAFE | 0.71 | 24% |
| MSCI Emg Mkts | 0.33 | 13% |
Liquidity Measures
| Avg. volume (000) | 103 |
| ADV traded (mns) | $7 |
| Turnover | 1.4% |
| Avg. Bid/Ask (% of price) | 0.20% |
Technical Indicators
| 30d moving avg. (EMA) | $66.58 |
| Relative strength (RSI) | 59 |
| MACD/Signal | 1.34/1.60 |
| Bollinger Bands (Upper/Lower) | $70.21/$66.51 |
| Short interest (% of AUM) | 14.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XPH |
Expenses vs. XPH |
ALTAR Score™ vs. XPH |
|---|---|---|---|---|
| IHE | iShares U.S. Pharmaceuticals ETF | 37.1% | +5 bp | +5.7% |
| PJP | Invesco Pharmaceuticals ETF | 32.2% | +22 bp | +7.8% |
| SBIO | ALPS Medical Breakthroughs ETF | 19.9% | +15 bp | +0.8% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 18.0% | +25 bp | -0.4% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 15.8% | +25 bp | +7.5% |
| BBP | Virtus LifeSci Biotech Products ETF | 13.9% | +44 bp | -2.7% |
| PPH | VanEck Pharmaceutical ETF | 13.7% | +1 bp | +8.4% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 13.4% | -6 bp | +3.0% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 12.6% | +44 bp | +0.8% |
| FXH | First Trust Health Care AlphaDEX Fund | 12.6% | +27 bp | +5.7% |
Risk and Returns: XPH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 8/9/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-0.8%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,402 funds in the US Equity category with an average
ALTAR Score™ of 5.2% and a standard deviation
of 2.0%. XPH's ALTAR Score™ is approximately -3.0 standard
deviations above the category average. This places XPH in the 1st percentile
among funds in the category.
Sell-Side Consensus
$72.94
PRICE TARGET
+3.4%
UPSIDE